Second Genome, Inc.
Records under this name other than patents Second Genome, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,150,982 | Microbial Ecology Shift Assay Formerly held In force · High confidence | In force | High confidence | |
| US 10,251,933 | Proteins for the Treatment of Epithelial Barrier Function Disorders Formerly held In force · High confidence | In force | High confidence | |
| US 11,207,376 | Proteins for the Treatment of Epithelial Barrier Function Disorders Formerly held In force · High confidence | In force | High confidence | |
| US 11,666,627 | Proteins for the Treatment of Epithelial Barrier Function Disorders Formerly held In force · High confidence | In force | High confidence | |
| US 12,371,456 | Proteins for the treatment of epithelial barrier function disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,168,677 | Proteins for the treatment of epithelial barrier function disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,174,293 | Proteins for the treatment of epithelial barrier function disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,344,584 | Gemella sanguinis as a biotherapeutic Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,273,198 | Proteins for the treatment of epithelial barrier function disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,186,364 | Proteins for the treatment of epithelial barrier function disorders Formerly held In force · From the USPTO record | In force | From the USPTO record |